Comparison of the bronchodilating effects of inhaled β2- agonists after methacholine challenge in a human lung reperfusion model

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 81, Issue 3, 2012, Pages 617-626

  Gnadt, Mirjam ^a   Trammer, Beatrice ^a   Kardziev, Boris ^b   Bayliss, Martin K ^c   Edwards, Chris D ^c   Schmidt, Michael ^a   Högger, Petra ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b Thoraxzentrum Bezirk Unterfranken   (Germany)

^c GLAXOSMITHKLINE   (United Kingdom)

Author keywords

GW597901; Isolated perfused lung; Nebulisation; PGE2; Salbutamol

Indexed keywords

GSK 597901; METHACHOLINE; PROSTAGLANDIN E2; SALBUTAMOL;

ARTICLE; BRONCHODILATING ACTIVITY; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENCY; HUMAN; HUMAN TISSUE; ISOLATED LUNG; LUNG PERFUSION; NEBULIZATION; PROVOCATION TEST; REPERFUSION;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; ALBUTEROL; BRONCHIAL PROVOCATION TESTS; BRONCHOCONSTRICTOR AGENTS; BRONCHODILATOR AGENTS; DELAYED-ACTION PREPARATIONS; DINOPROSTONE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LUNG; METHACHOLINE CHLORIDE; REPERFUSION; SULFONAMIDES; TIME FACTORS;

EID: 84863782327     PISSN: 09396411     EISSN: 18733441     Source Type: Journal    
DOI: 10.1016/j.ejpb.2012.04.013     Document Type: Article

References (50)

1. E.D. Bateman, S.S. Hurd, P.J. Barnes, J. Bousquet, J.M. Drazen, M. FitzGerald, P. Gibson, K. Ohta, P. O'Byrne, S.E. Pedersen, E. Pizzichini, S.D. Sullivan, S.E. Wenzel, H.J. Zar, Global strategy for asthma management and prevention: GINA executive summary, Eur. Respir. J. 31 (2008) 143-178.
2. K.F. Rabe, S. Hurd, A. Anzueto, P.J. Barnes, S.A. Buist, P. Calverley, Y. Fukuchi, C. Jenkins, R. Rodriguez-Roisin, C. van Weel, J. Zielinski, Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary, Am. J. Respir. Crit. Care Med. 176 (2007) 532-555. (Pubitemid 47403272)
3. M. Cazzola, M.G. Matera, Novel long-acting bronchodilators for COPD and asthma, Br. J. Pharmacol. 155 (2008) 291-299.
4. P.A. Procopiou, V.J. Barrett, N.J. Bevan, K. Biggadike, P.R. Butchers, D.M. Coe, R. Conroy, D.D. Edney, R.N. Field, A.J. Ford, S.B. Guntrip, B.E. Looker, I.M. McLay, M.J. Monteith, V.S. Morrison, P.J. Mutch, S.A. Richards, R. Sasse, C.E. Smith, Synthesis and structure-activity relationships of long-acting beta2 adrenergic receptor agonists incorporating arylsulfonamide groups, J. Med. Chem. 52 (2009) 2280-2288.
5. M. Cazzola, M.G. Matera, J. Lötvall, Ultra long-acting beta 2-agonists in development for asthma and chronic obstructive pulmonary disease, Expert Opin. Investig. Drugs 14 (2005) 775-783. (Pubitemid 41030946)
6. C. Bosquillon, Drug transporters in the lung - do they play a role in the biopharmaceutics of inhaled drugs?, J Pharm. Sci. 99 (2010) 2240-2255.
7. C. Ehrhardt, C. Kneuer, C. Bies, C.M. Lehr, K.J. Kim, U. Bakowsky, Salbutamol is actively absorbed across human bronchial epithelial cell layers, Pulm. Pharmacol. Ther. 18 (2005) 165-170. (Pubitemid 40222110)
8. M. Gnadt, B. Trammer, M. Freiwald, B. Kardziev, M.K. Bayliss, C.D. Edwards, M. Schmidt, G. Friedel, P. Högger, Methacholine delays pulmonary absorption of inhaled beta(2)-agonists due to competition for organic cation/carnitine transporters, Pulm. Pharmacol. Ther. 25 (2012) 124-134.
9. J. Lötvall, Pharmacological similarities and differences between beta2-agonists, Respir. Med. 95 (Suppl. B) (2001) S7-11.
10. A. Linder, G. Friedel, P. Fritz, K.T. Kivisto, M. McClellan, H. Toomes, The ex-vivo isolated, perfused human lung model: description and potential applications, Thorac. Cardiovasc. Surg. 44 (1996) 140-146. (Pubitemid 26246968)
11. P. Högger, Explaining pulmonary pharmacokinetics of inhaled corticosteroids: how close to in vivo reality can we get? in: P.R. Byron (Ed.), Respiratory Drug Delivery X, Davis-Horwood International, Raleigh, NC, 2006. pp. 205-217.
12. A.D. Chediak, A. Wanner, The circulation of the airways: anatomy, physiology and potential role in drug delivery to the respiratory tract, Adv. Drug Deliv. Rev. 5 (1990) 11-18. (Pubitemid 20333013)
13. F.J. Miller, R.R. Mercer, J.D. Crapo, Lower respiratory tract structure of laboratory animals and humans: dosimetry implications, Aerosol Sci. Technol. 18 (1993) 257-271. (Pubitemid 23106643)
14. B. Asgharian, J.T. Kelly, E.W. Tewksbury, Respiratory deposition and inhalability of monodisperse aerosols in Long-Evans rats, Toxicol. Sci. 71 (2003) 104-111. (Pubitemid 36163710)
15. M. Freiwald, A. Valotis, A. Kirschbaum, M. McClellan, T. Mürdter, P. Fritz, G. Friedel, M. Thomas, P. Högger, Monitoring the initial pulmonary absorption of two different beclomethasone dipropionate aerosols employing a human lung reperfusion model, Respir. Res. 6 (2005) 21.
16. A. Woodcock, D. Acerbi, G. Poli, Modulite technology: pharmacodynamic and pharmacokinetic implications, Respir. Med. 96 (Suppl. D) (2002) S9-15.
17. D.W. Cockcroft, Direct challenge tests: airway hyperresponsiveness in asthma: its measurement and clinical significance, Chest 138 (2010) 18S-24S.
18. D.C. Grootendorst, K.F. Rabe, Mechanisms of bronchial hyperreactivity in asthma and chronic obstructive pulmonary disease, Proc. Am. Thorac. Soc. 1 (2004) 77-87.
19. A. Cartier, J.L. Malo, P. Begin, M. Sestier, R.R. Martin, Time course of the bronchoconstriction induced by inhaled histamine and methacholine, J. Appl. Physiol. 54 (1983) 821-826. (Pubitemid 13115088)
20. M. Sue-Chu, J.D. Brannan, S.D. Anderson, N. Chew, L. Bjermer, Airway hyperresponsiveness to methacholine, adenosine 5-monophosphate, mannitol, eucapnic voluntary hyperpnoea and field exercise challenge in elite cross-country skiers, Br. J. Sports Med. 44 (2010) 827-833.
21. R.O. Crapo, R. Casaburi, A.L. Coates, P.L. Enright, J.L. Hankinson, C.G. Irvin, N.R. MacIntyre, R.T. McKay, J.S. Wanger, S.D. Anderson, D.W. Cockcroft, J.E. Fish, P.J. Sterk, Guidelines for Methacholine and Exercise Challenge Testing-1999. This Official Statement of the American Thoracic Society was Adopted by the ATS Board of Directors, July 1999, Am. J. Respir. Crit. Care. Med. 161 (2000) 309-329.
22. H.J. van der Woude, T.H. Winter, R. Aalbers, Decreased bronchodilating effect of salbutamol in relieving methacholine induced moderate to severe bronchoconstriction during high dose treatment with long acting beta2 agonists, Thorax 56 (2001) 529-535. (Pubitemid 32588531)
23. R.E. Jonkers, T.A. Bantje, R. Aalbers, Onset of relief of dyspnoea with budesonide/formoterol or salbutamol following methacholine-induced severe bronchoconstriction in adults with asthma: a double-blind, placebo-controlled study, Respir. Res. 7 (2006) 141.
24. D. Fishwick, L. Bradshaw, C. Macdonald, R. Beasley, D. Gash, T. Bengtsson, E. Bondesson, L. Borgstrom, Cumulative and single-dose design to assess the bronchodilator effects of beta2-agonists in individuals with asthma, Am. J. Respir. Crit. Care Med. 163 (2001) 474-477. (Pubitemid 32158531)
25. F. Lavorini, P. Geri, L. Mariani, C. Marmai, N.M. Maluccio, M. Pistolesi, G.A. Fontana, Speed of onset of bronchodilator response to salbutamol inhaled via different devices in asthmatics: a bioassay based on functional antagonism, Br. J. Clin. Pharmacol. 62 (2006) 403-411. (Pubitemid 44401523)
26. P.H. Eilers, A perfect smoother, Anal. Chem. 75 (2003) 3631-3636. (Pubitemid 36871257)
27. G. Phillips, J. Harris, Polynomial filters for data spectra with outlying or missing observations: application to charge-coupled-device-detected Raman spectra contaminated by cosmic rays, Anal. Chem. 62 (1990) 2351-2357.
28. H.A. David, H.O. Hartley, E.S. Pearson, The distribution of the ratio, in a single normal sample of the range to standard deviation, Biometrika 41 (1954) 482-493.
29. E.S. Pearson, M.A. Stephens, The ration of range to standard deviation in the same normal sample, Biometrika 51 (1964) 484-487.
30. P.A. Corris, E. Neville, S. Nariman, G.J. Gibson, Dose-response study of inhaled salbutamol powder in chronic airflow obstruction, Thorax 38 (1983) 292-296. (Pubitemid 13122632)
31. S.J. Farr, A.M. Rowe, R. Rubsamen, G. Taylor, Aerosol deposition in the human lung following administration from a microprocessor controlled pressurised metered dose inhaler, Thorax 50 (1995) 639-644.
32. S. Newman, S. Malik, R. Hirst, G. Pitcairn, A. Heide, J. Pabst, A. Dinkelaker, W. Fleischer, Lung deposition of salbutamol in healthy human subjects from the MAGhaler dry powder inhaler, Respir. Med. 96 (2002) 1026-1032. (Pubitemid 35386119)
33. E.M. Rosethorne, R.J. Turner, R.A. Fairhurst, S.J. Charlton, Efficacy is a contributing factor to the clinical onset of bronchodilation of inhaled beta(2)-adrenoceptor agonists, Naunyn Schmiedebergs Arch. Pharmacol. 382 (2010) 255-263.
34. P.J. Barnes, Distribution of receptor targets in the lung, Proc. Am. Thorac. Soc. 1 (2004) 345-351.
35. A.D. Fryer, D.B. Jacoby, Muscarinic receptors and control of airway smooth muscle, Am. J. Respir. Crit. Care Med. 158 (1998) S154-160. (Pubitemid 28536584)
36. N.B. Charan, J. Wolf, M. Henrichs, J.M. Williams, R. Sullivan, L.J. Ashworth, Are inhaled drugs delivered to the bronchial smooth muscles through the bronchial circulation?, Arch Physiol. Biochem. 111 (2003) 331-333. (Pubitemid 40292072)
37. J. Yu, Y.W. Chien, Pulmonary drug delivery: physiologic and mechanistic aspects, Crit. Rev. Ther. Drug Carrier Syst. 14 (1997) 395-453. (Pubitemid 28036074)
38. L. Prieto, V. Gutierrez, C. Morales, J. Marin, Differences in sensitivity, maximal response and position of the concentration-response curve to methacholine between asthmatics, patients with allergic rhinitis and healthy subjects, Respir. Med. 92 (1998) 88-94. (Pubitemid 28112048)
39. O.P. Seppälä, E. Iisalo, Measuring the bronchial effect of bronchodilating drugs in healthy subjects after methacholine provocation. Salbutamol as a model drug, Eur. J. Clin. Pharmacol. 39 (1990) 559-563.
40. P. Vineis, L. Airoldi, F. Veglia, L. Olgiati, R. Pastorelli, H. Autrup, A. Dunning, S. Garte, E. Gormally, P. Hainaut, C. Malaveille, G. Matullo, M. Peluso, K. Overvad, A. Tjonneland, F. Clavel-Chapelon, H. Boeing, V. Krogh, D. Palli, S. Panico, R. Tumino, B. Bueno-De-Mesquita, P. Peeters, G. Berglund, G. Hallmans, R. Saracci, E. Riboli, Environmental tobacco smoke and risk of respiratory cancer and chronic obstructive pulmonary disease in former smokers and never smokers in the EPIC prospective study, BMJ 330 (2005) 277.
41. A.S. Buist, M.A. McBurnie, W.M. Vollmer, S. Gillespie, P. Burney, D.M. Mannino, A.M. Menezes, S.D. Sullivan, T.A. Lee, K.B. Weiss, R.L. Jensen, G.B. Marks, A. Gulsvik, E. Nizankowska-Mogilnicka, International variation in the prevalence of COPD (the BOLD study): a population-based prevalence study, Lancet 370 (2007) 741-750. (Pubitemid 47321907)
42. J. Congleton, M.F. Muers, The incidence of airflow obstruction in bronchial carcinoma, its relation to breathlessness, and response to bronchodilator therapy, Respir. Med. 89 (1995) 291-296.
43. R.E. Kanner, J.E. Connett, M.D. Altose, A.S. Buist, W.W. Lee, D.P. Tashkin, R.A. Wise, Gender difference in airway hyperresponsiveness in smokers with mild COPD. The lung health study, Am. J. Respir. Crit. Care Med. 150 (1994) 956-961. (Pubitemid 24318019)
44. M. Huang, M. Stolina, S. Sharma, J.T. Mao, L. Zhu, P.W. Miller, J. Wollman, H. Herschman, S.M. Dubinett, Non-small cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance in lymphocytes and macrophages: up-regulation of interleukin 10 and down-regulation of interleukin 12 production, Cancer Res. 58 (1998) 1208-1216. (Pubitemid 28183210)
45. H. Wolff, K. Saukkonen, S. Anttila, A. Karjalainen, H. Vainio, A. Ristimaki, Expression of cyclooxygenase-2 in human lung carcinoma, Cancer Res. 58 (1998) 4997-5001. (Pubitemid 28521147)
46. D. Hughes, T. Otani, P. Yang, R.A. Newman, R.K. Yantiss, N.K. Altorki, J.L. Port, M. Yan, S.D. Markowitz, M. Mazumdar, H.H. Tai, K. Subbaramaiah, A.J. Dannenberg, NAD+ dependent 15-hydroxyprostaglandin dehydrogenase regulates levels of bioactive lipids in non-small cell lung cancer, Cancer Prev. Res. (Phila) 1 (2008) 241-249.
47. Y. Zheng, J.D. Ritzenthaler, X. Sun, J. Roman, S. Han, Prostaglandin E2 stimulates human lung carcinoma cell growth through induction of integrin-linked kinase: the involvement of EP4 and Sp1, Cancer Res. 69 (2009) 896-904.
48. J.M. Hartney, K.G. Coggins, S.L. Tilley, L.A. Jania, A.K. Lovgren, L.P. Audoly, B.H. Koller, Prostaglandin E2 protects lower airways against bronchoconstriction, Am. J. Physiol. Lung Cell. Mol. Physiol. 290 (2006) L105-113.
49. J.R. Sheller, D. Mitchell, B. Meyrick, J. Oates, R. Breyer, EP(2) receptor mediates bronchodilation by PGE(2) in mice, J. Appl. Physiol. 88 (2000) 2214-2218. (Pubitemid 30453930)
50. A. Buvanendran, J.S. Kroin, R.A. Berger, N.J. Hallab, C. Saha, C. Negrescu, M. Moric, M.S. Caicedo, K.J. Tuman, Upregulation of prostaglandin E2 and interleukins in the central nervous system and peripheral tissue during and after surgery in humans, Anesthesiology 104 (2006) 403-410.